Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines reports clinical trial results for a combination of Zoldonrasib and Daraxonrasib in treating metastatic pancreatic cancer.
- Intelligence Anchor: Revolution Medicines shares promising data around KRAS drug combination
- Core Takeaway: Revolution Medicines reports clinical trial results for a combination of Zoldonrasib and Daraxonrasib in treating metastatic pancreatic cancer.
- Signal Velocity: 3 score across 5 independent media sources and 5 indexed articles.
- Forecast Model: Story predicted to decelerate within 24h.
Coverage (5)
- Anirban Maitra։ Data on Zoldonrasib Plus Daraxonrasib in 2nd and 3rd Line Metastatic Pancreatic Cancer Oncodaily · 95d ago
- Practice-Changing Data in GI Oncology Medscape · 95d ago
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Yahoo Finance · 95d ago
- Experimental cancer drug brings time and hope for patients WSAW · 95d ago
- Revolution Medicines shares promising data around KRAS drug combination Endpoints News · 95d ago
What happened
Revolution Medicines has presented Phase 1/2 clinical trial data for its drug combination, Zoldonrasib and Daraxonrasib. The study focuses on patients with RAS G12D metastatic pancreatic cancer, specifically targeting those in second and third-line treatment phases.
Coverage from Endpoints News, Yahoo Finance, and Oncodaily highlights the presentation of these results at the ESMO Gastrointestinal Cancers Congress 2026. Medscape describes the findings as practice-changing in the field of GI oncology, while WSAW reports on the treatment's impact on patient outcomes.
Future developments will depend on the continued evaluation of these combination regimens. Coverage does not yet specify long-term survival metrics or the timeline for subsequent regulatory filings.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 93d ago.
Questions people are asking
What is the drug combination being tested?
The regimen consists of Zoldonrasib and Daraxonrasib.
Which patient group is the focus of this data?
The clinical data concerns patients with RAS G12D metastatic pancreatic cancer.
Where were these results presented?
The data was presented at the ESMO Gastrointestinal Cancers Congress 2026.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Will this trend continue gaining momentum or fade within 24 hours?
Cast your anonymous vote to register reader sentiment on news cycle velocity.
Topics
Related trends
Mike Detillier dies after brief battle with cancer, revered as respected college & pro football analyst for 40+ years on WWL
New Orleans loses its radio‑football sage just weeks after a terminal cancer diagnosis.
Only 13% survive this cancer. A blood test just detected 90% of early cases
A new blood-based mRNA diagnostic test is showing potential in identifying early-stage pancreatic cancer, a condition with historically low survival rates.
A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses
A new experimental KRAS-targeted vaccine shows promise in early trials for preventing pancreatic cancer in high-risk individuals.
A breakthrough in pancreatic cancer has experts excited
Medical experts report promising clinical results for a new pancreatic cancer treatment targeting KRAS-mutated tumors.
Pancreatic cancer breakthrough has big implications for early detection effort - San Diego Union-Tribune
A pancreatic cancer pill under accelerated review could redefine treatment—and early detection—of a deadly disease.
Harvard gastroenterologist reveals 7 silent symptoms of pancreatic cancer everyone should know
A Harvard gastroenterologist’s warning on pancreatic cancer symptoms sparks global health alerts